

BRS/RA Integrated Conference Programme 2006

WEDNESDAY 3rd MAY 2006

8.30

REGISTRATION

10.00-12.00

Main Auditorium	Queens Suite 1	Queens Suite 2	Kings Suite
<p>CHRONIC KIDNEY DISEASE Chair: Steve Smith, Birmingham Heartlands Hospital, President BRS</p> <p>O1 Variability in referral patterns to renal services in Kent H J Hobbs, Kent and Canterbury Hospital</p> <p>O2 Risk of CKD progression and mortality related to renal function in patients aged 61-65 years MW Taal, Derby City General Hospital</p> <p>O3 Recognition of a large cohort of CKD patients in West Lincolnshire by a primary care-based disease management programme (DMP) NT Richards, Tipton Dialysis Unit, Brimingham</p> <p>O4 Area deprivation predicts development of CKD in the population AK Bello, Sheffield Kidney Institute</p> <p>O5 A systematic Diabetic Renal Service – better for patients and clinicians HC Rayner, Birmingham Hearlands Hospital</p> <p>O6 The value of routine renal ultrasound (US) in patients with CKD KPG Harris, Leicester General Hospital</p>	<p>LABORATORY SCIENCE: CELL COMMUNICATION Chair: Jeremy Hughes, University of Edinburgh School of Medicine</p> <p>Cross-talk between glomerular cells. Guest Speaker: Moin Saleem, Reader in Paediatric Nephrology, University of Bristol</p> <p>O9 VEGF_{165b} defines the phenotype of the normal glomerulus SJ Harper, University of Bristol</p> <p>O10 Interferon Beta attenuates proteinuria in 3 models of experimental glomerular injury and modulates barrier properties of human glomerular endothelial cells and podocytes in culture S C Satchell, University of Bristol</p> <p>O11 The differential role of Ras Isoforms in TGFβ1 induced connective tissue growth factor expression in human proximal tubule epithelial cells MK Phanish, SW Thames Institute for Renal Research, Carshalton</p> <p>O12 The hyperproliferation of PKD1 cystic cells to insulin-like growth factor-1 and cAMmP is mediated by a Ras/Raf dependent signalling pathway</p>	<p>TRANSPLANT FORUM Sponsored by: Novartis Chair: Phil Dyer, Manchester Royal Infirmary</p> <p>The impact of 3 initiatives for improving donation rates in the UK. Guest Speaker: Lisa Burnapp, Nurse Consultant, Living Transplantation, Guy's and St Thomas's Hospital Trust, London</p> <p>O15 Randomised controlled trial of open versus laparoscopic live donor nephrectomy ML Nicholson, University Hospitals of Leicester</p> <p>O16 Outcome of renal transplantation in 300 children between 1973 and 2000 R Shroff, Great Ormand Street Hospital for Children NHS Trust, London</p> <p>O17 Antibody incompatible transplantation – demand and outcomes RM Higgins, Coventry and Warwickshire NHS Trust</p> <p>O18 ABO incompatible live donor transplantation with Rituximab</p>	<p>EXERCISE AND FRAILITY Chair: Tom Mercer, Queen Mary University College, Edinburgh</p> <p>The epidemiology of muscle wasting and weakness in renal failure. Guest Speaker: Patrick Naish, Consultant Nephrologist, North Staffordshire Infirmary</p> <p>O21 The Acidosis-Sensing amino acid pump SNAT2 determines intracellular levels of the anabolic amino acids L-Gln and L-Leu in Skeletal Muscle Cells A Bevington, Leicester General Hospital</p> <p>O22 Functionally significant progressive skeletal muscle wasting in CKD4 and CKD5 (PD and HD) patients CW McIntyre, Derby City General Hospital</p> <p>O23 Can a Structured, Multidisciplinary Programme Combining Exercise, Diet and Orlistat Achieve Significant Weight Loss and Improved Functional Ability in Patients with CKD ? S A Cook, Kings College Hospital,</p>

<p>O7 A longitudinal study of extracellular fluid in patients with CKD LM Wells, York Hospital</p> <p>O8 Outcomes in CKD : Prognostic role of ischaemia and subclinical left ventricular abnormalities and impact of transplantation DJ Rakhit, University of Queensland, Brisbane, Australia</p>	<p>E Parker, Sheffield Kidney Institute</p> <p>O13 Toll-like receptor 4 is required on both bone marrow derived and non-bone marrow derived cells for maximal neutrophil influx in heterologous nephrotoxic nephritis HJ Brown, King's College London School of Medicine</p> <p>O14 Investigating the role of tumour necrosis factor alpha in graft rejection across a minor (hy) mismatch skin transplantation model PE Herbert, Imperial College London</p>	<p>JW Galliford, West London Renal Transplant Centre, Hammersmith</p> <p>O19 Vitamin D status in long-term renal transplant recipients AS Stavroulopoulos, Nottingham City Hospital NHS Trust</p> <p>O20 Early neural regeneration after pancreas transplantation detected by corneal confocal microscopy: A pilot study S Mehra, Manchester Royal Infirmary</p>	<p>London</p> <p>O24 Effects of a 12 month training programme on quality of life, functional ability and nutritional status in long term HD patients S Smith, Queen Margaret University College, Edinburgh</p> <p>Towards exercise as part of routine care for chronic kidney disease. Guest Speaker: Jamie MacDonald, Exercise Physiologist, University of Bangor, Wales</p>
---	---	--	---

LUNCH & EXHIBITION - Hall Q

MODERATED POSTER SESSION & EXHIBITION - Hall D

Main Auditorium

PLENARY 1: VASCULAR ACCESS

Co-Chair: Chris Winearls, Oxford Kidney Unit & Mick Kumwenda, Glan Clwyd Hospital, Rhyl

Vascular Access - the current UK scene.

Guest Speaker: Dr Richard Fluck, Consultant Nephrologist, Derby City General Hospital

Why does vascular access fail?

Guest Speaker: Dr Pietro Ravani, Consultant Nephrologist, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy

Vascular access in the complex case.

Guest Speaker: Dr Eric Chemla, Consultant Surgeon and Honorary Senior Lecturer, St Georges Hospital, London

Planning a vascular access service.

Guest Speaker: Ms Mercia Spare, Project Leader, University Hospital of Birmingham

Vascular access and sepsis - the curse of the dialysis unit.

Guest Speaker: Dr David Goldsmith, Consultant Nephrologist, Guy's & St Thomas's Hospital Trust, London

15.30-16.00	COFFEE & EXHIBITION - Hall Q			POSTERS - Hall D
16.00-17.30	Main Auditorium	Queens Suite 1	Queens Suite 2	Kings Suite
	<p>MODERNISING RENAL SERVICES 1. Chair: Rachael Lewis, Department of Health</p> <p>Escaping from the</p>	<p>LABORATORY SCIENCE: Renal Immunity & Inflammation Chair: Alan Salama, Imperial College London</p> <p>O29 Toll-like</p>	<p>CLINICAL TRIALS AND TRANSLATIONAL MEDICINE Chair: Dr David Jayne Addenbrook's Hospital Cambridge</p> <p>Mycophenolate</p>	<p>Vascular Access Chair: Eric Chemla, St. George's Hospital, London</p> <p>O35 Vascular Access – A national survey of the prevalent dialysis population on behalf of the Renal Association</p>

<p>anachronism of medical practice Dr Charlie Tomson, Consultant Nephrologist, Southmead Hospital, Bristol</p> <p>O25 Effective management of hypertension through nurse prescribing RM Anson, Royal suxxes County Hospital</p> <p>O26 Audit of the safety and efficacy of a computerised decision support system for the management of renal bone disease EJ Lindley, Leeds Teaching Hospitals NHS Trust</p> <p>O27 Do Once and Share Experiences of the Renal NpFIT Programme B Stribling, Hinckley & Bosworth PCT, Market Bosworth, Leicestershire</p> <p>O28 What the politicians thought about kidney disease during the May 2005 General Election - 45,000 Survey forms sent out by Kidney patients T F Statham OBE, national Kidney Federation, Worksop Nottinghamshire</p>	<p>receptor 2 agonists exacerbate disease in accelerated nephrotoxic nephritis HJ Brown, King's College London School of Medicine</p> <p>O30 CD46 is a key protein responsible for bacterial invasion of the urinary tract K Li, King's College London</p> <p>O31 Transfer of tolerance to naïve recipients by splenic T cells from donors with experimental autoimmune glomerulonephritis treated with an anti-ICOSL monoclonal antibody J Reynolds, Imperial College London</p> <p>O32 Differential suppressors of cytokine signalling (SOCS) expression by macrophages in acute glomerulonephritis M Wilson, University of Aberdeen</p> <p>Inhibitory Fc gamma receptors and SLE. Guest Speaker: Ken Smith, Reader in Renal Medicine, University of Cambridge</p>	<p>mofetil or intravenous cyclophosphamide for lupus nephritis: An appraisal of the Ginzler trial. Guest Speaker: Dwomoa Adu, Consultant Nephrologist. Queen Elizabeth Hospital, Birmingham</p> <p>ASTRAL update Philip Kalra, Hope Hospital, Salford</p> <p>EUVAS update Lorraine Harper, Queen Elizabeth Hospital, Birmingham</p> <p>Membranous nephropathy trial update Peter Mathieson, Southmead Hospital, Bristol</p> <p>SHARP update Martin Landray, Radcliffe Infirmary, Oxford</p> <p>O33 Resistance to the increase in GFR induced by rhIGF-I in non-diabetic patients with end stage renal disease Y Kuan, Sheffield Kidney Institute</p> <p>O34 Campath and Medium Dose Tacrolimus Monotherapy in renal transplantation: one year pilot study K Chan, West London Renal and Transplant Centre, Hammersmith</p>	<p>Clinical Directors' Forum and UK Renal Registry and Kidney Research UK R Rao, UK Renal Registry, Southmead Hospital, Bristol</p> <p>O36 Incident access in the UK dialysis population - results of a UK survey on behalf of the Renal Association Clinical Directors' Forum and UK Renal Registry and Kidney Research UK R Rao, UK Renal Registry, Southmead Hospital, Bristol</p> <p>O37 DOPPS Estimates of Patient Life Years Attributable to Modifiable Haemodialysis Practices in the United Kingdom. HC Rayner, Birmingham Heartlands Hospital</p> <p>O38 Age and history of cardiovascular disease or diabetes are not contra-indications to arterio-venous fistula creation B Yeung, Glasgow Royal Infirmary</p> <p>O39 Is basilic vein transposition a real alternative to bypass? Results of a prospective trial monitored over two years by Transonic L Anderson, St. Georges Hospital, London</p> <p>O40 Radical transformation of vascular access provision to a more patient-focused service R Murray, Liverpool University Hospital</p>
--	--	--	--

17.45-18.45 GUEST LECTURE Main Auditorium
Chair: John Feehally, Leicester General Hospital, President, The Renal Association
'Healthcare is a risky business' Prof Aidan Halligan, Director of Clinical Governance, NHS, Leicester, UK

18.50-21.00 WELCOME RECEPTION IN THE Hall Q

